Treatment of systemic lupus erythematosus with cyclophosphamide

被引:0
作者
Backhaus, M
Hiepe, F
机构
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 1997年 / 56卷 / 04期
关键词
systemic lupus erythematosus; lupus nephritis; cyclophosphamide; methylprednisolone;
D O I
10.1007/s003930050033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cyclophosphamide is a potent immunosuppressive drug which is widely used to treat renal and central nervous system manifestation of Systemic Lupus Erythematosus (SLE). It is employed especially to prevent renal failure in lupus nephritis. Within the last decade intravenous cyclophosphamide bolus therapy has become the standard therapy in severe SLE due to its tendency towards a higher efficacy and fewer side effects as compared to oral application. Studies on the slightly more cost-effective oral cyclophosphamide bolus therapy have recently been published, however, there are no data on long-term results yet. Here, we review the effects and side effects of cyclophosphamide as well as recent clinical studies on cyclophosphamide bolus therapy in SLE. Because of the possible side effects, especially the high risk of malignancies, which sharply increases at a cumulative dose of approximately 60 g, cyclophosphamide should be used cautiously. Cyclophosphamide bolus therapy should only be performed in hospitals with special experience.
引用
收藏
页码:178 / 189
页数:12
相关论文
共 50 条
  • [31] Protein-losing enteropathy associated with systemic lupus erythematosus: response to cyclophosphamide
    Gláucio R. Werner de Castro
    Simone Appenzeller
    Manoel B. Bértolo
    Lílian Tereza Lavras Costallat
    Rheumatology International, 2005, 25 : 135 - 138
  • [32] Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus
    Cunha, Ines
    Saavedra, Maria Joao
    Da Silva, Jose Antonio Pereira
    Malcata, Armando
    ACTA REUMATOLOGICA PORTUGUESA, 2008, 33 (01): : 69 - 76
  • [33] IMMUNOLOGICAL EFFECTS OF PLASMAPHERESIS SYNCHRONIZED WITH PULSE CYCLOPHOSPHAMIDE IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    DAU, PC
    CALLAHAN, J
    PARKER, R
    GOLBUS, J
    JOURNAL OF RHEUMATOLOGY, 1991, 18 (02) : 270 - 276
  • [34] Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus
    Vlachoyiannopoulos, Panayiotis G.
    Toya, Sophie P.
    Katsifis, Ghikas
    Zintzaras, Elias
    Tzioufas, Athanasios G.
    Moutsopoulos, Haralampos M.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (09) : 1768 - 1775
  • [35] Effects of IV cyclophosphamide on HIV viral replication in a patient with systemic lupus erythematosus
    Alonso, CM
    Lozada, CJ
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2000, 18 (04) : 510 - 512
  • [36] Protein-losing enteropathy associated with systemic lupus erythematosus:: response to cyclophosphamide
    de Castro, GRW
    Appenzeller, S
    Bértolo, MB
    Costallat, LTL
    RHEUMATOLOGY INTERNATIONAL, 2005, 25 (02) : 135 - 138
  • [37] Low dosage use of cyclophosphamide improves the survival of patients with systemic lupus erythematosus
    Yoosuf Ali Ashraf Muhammad Hussenbocus
    Ziyi Jin
    Wenyou Pan
    Lin Liu
    Min Wu
    Huaixia Hu
    Xiang Ding
    Hua Wei
    Yaohong Zou
    Xian Qian
    Meimei Wang
    Jian Wu
    Juan Tao
    Jun Tan
    Zhanyun Da
    Miaojia Zhang
    Jing Li
    Xuebing Feng
    Lingyun Sun
    Clinical Rheumatology, 2022, 41 : 2043 - 2052
  • [38] High-dose cyclophosphamide for severe systemic lupus erythematosus
    Gladstone, DE
    Prestrud, AA
    Pradhan, A
    Styler, MJ
    Topolsky, DL
    Crilley, PA
    Hoch, S
    Huppert, A
    Brodsky, I
    LUPUS, 2002, 11 (07) : 405 - 410
  • [39] Pregnancy in patients with systemic lupus erythematosus after cyclophosphamide therapy
    Sen, Mitali
    Kurl, Anu
    Khosroshahi, Arezou
    LUPUS, 2021, 30 (09) : 1509 - 1514
  • [40] Systemic lupus erythematosus
    Tanaka, Yoshiya
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2022, 36 (04):